BLA 761127 · Revance Therapeutics, Inc.
Daxxify
Daxibotulinumtoxina-Lanm · Intramuscular, Subcutaneous · Acetylcholine Release Inhibitor; Neuromuscular Blocker
NovelOrphanCDER novel approval, Sep 7, 2022: To treat moderate-to-severe glabellar lines associated with corrugator and/or procerus muscle activity
Last checked: Nov 20, 2026Latest source record: Aug 11, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2022
Sep 7, 2022
Approved uses
2
Original approval plus efficacy supplements
Registered trials
1,077
324 Phase 3, 72 recruiting
FAERS reports
5,969
5,181 serious, 1,844 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: DISTANT SPREAD OF TOXIN EFFECT The effects of all botulinum toxin products, including DAXXIFY, may spread from the area of injection to produce symptoms consistent with botulinum toxin effects. These symptoms have been reported hours to weeks after injection. Swallowing and breathing difficulties can be life-threatening, and there have been reports of death. The risk of symptoms is probably greatest in children treated for spasticity, an unapproved use for DAXXIFY, but symptoms can also occur in adults, particularly in those patients who have an underlying condition that would predispose them to these symptoms [see Warnings and Precautions (5.1) ]. WARNING: DISTANT SPREAD OF TOXIN EFFECT See full prescribing information for complete boxed warning. The effects of DAXXIFY and all botulinum toxin products may spread from the area of injection to produce symptoms consistent with...
What it is approved for
From the label in effect Nov 4, 2026.
DAXXIFY is an acetylcholine release inhibitor and neuromuscular-blocking agent indicated for: Temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/ or procerus muscle activity in adult patients. ( 1.1 ) The treatment of cervical dystonia in adult patients. ( 1.2 ) 1.1 Glabellar Lines DAXXIFY is indicated for the temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adult patients. 1.2 Cervical Dystonia DAXXIFY is indicated for the treatment of cervical dystonia in adult patients.
Mechanism: DAXXIFY blocks neuromuscular transmission at the neuromuscular junction by inhibiting the release of acetylcholine. This inhibition occurs as the neurotoxin cleaves SNAP-25, a protein necessary for the successful docking and release of acetylcholine vesicles within nerve endings. Recovery of neurotransmission occurs gradually as the neuromuscular junction recovers from SNAP-25 cleavage and as new nerve endings are formed.
Therapeutic areas: Pain and anesthesia
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Aug 11, 2023 Supplement 2 · Efficacy OrphanLetterLabelMedication Guide
- Sep 7, 2022 Original approval · Type 1 - New Molecular Entity NovelLetterLabelReview
1 products under this application
- DAXXIFY · DAXIBOTULINUMTOXINA-LANM 0.1ML · INJECTABLE, INTRAMUSCULAR, SUBCUTANEOUS · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Daxibotulinumtoxina" as an intervention, any sponsor and status, largest first.
- Safety of Single and Repeat Treatments of DaxibotulinumtoxinA for Injection for Treatment of Moderate to Severe Glabellar LinesPivotal-lookingCompleted
Revance Therapeutics, Inc.Industry
NCT03004248 · 2,691 participants · Start Dec 9, 2016 · Primary completion Oct 17, 2018
Drug: Botulinum Toxins, Type A · For: Glabellar Frown Lines
Sites: Birmingham, Alabama; Beverly Hills, California; Encinitas, California · 61 sites in all
- Using Botox to Treat Patients With Idiopathic ClubfootStatus unknown
University of British ColumbiaAcademic, hospital or other
NCT00474032 · 2,000 participants (planned) · Start Mar 2003 · Primary completion Mar 2023
Drug: Botulinum Toxin (Type A) injection (10 U/Kg) · For: Clubfoot
Sites: Vancouver, Canada
- A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Episodic MigrainePivotal-lookingActive, not recruiting
Merz Therapeutics GmbHIndustry
NCT07018700 · 997 participants · Start Aug 21, 2025 · Primary completion Mar 2027
Drug: Xeomin; Placebo · For: Episodic Migraine
Sites: Chandler, Arizona; Phoenix, Arizona; Little Rock, Arkansas · 110 sites in all
- Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Crow's Feet Lines and Frown LinesPivotal-lookingCompleted
AllerganAbbVie (ABBV)
NCT01189760 · 917 participants · Start Sep 1, 2010 · Primary completion Mar 1, 2011
Drug: onabotulinumtoxinA 24 U; onabotulinumtoxinA 44 U and 1 more · For: Facial Rhytides; Crow's Feet Lines; Glabellar Lines
Sites: Newport Beach, California; Vancouver, Canada; Antibes, France · 4 sites in all
- Long Term Follow-up Study of Safety and Efficacy of Botulinum Toxin Type A for the Treatment of Patients With Idiopathic Overactive Bladder With Urinary IncontinencePivotal-lookingCompleted
AllerganAbbVie (ABBV)
NCT00915525 · 829 participants · Start Feb 1, 2010 · Primary completion Aug 5, 2014
Drug: botulinum toxin Type A · For: Overactive Bladder; Urinary Incontinence
Sites: Newport Beach, California; Ghent, Belgium; Victoria, Canada · 8 sites in all
- A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Chronic MigrainePivotal-lookingActive, not recruiting
Merz Therapeutics GmbHIndustry
NCT07018713 · 808 participants · Start Aug 21, 2025 · Primary completion Mar 2027
Drug: Xeomin; Placebo · For: Chronic Migraine
Sites: Chandler, Arizona; Phoenix, Arizona; Little Rock, Arkansas · 111 sites in all
- Safety and Efficacy of NT 201 (IncobotulinumtoxinA [Xeomin]) in the Treatment of Glabellar Frown LinesPivotal-lookingCompleted
Merz Pharmaceuticals GmbHIndustry
NCT00512135 · 801 participants · Start Jun 18, 2007 · Primary completion Dec 28, 2009
Drug: IncobotulinumtoxinA (Xeomin) (20 units) · For: Glabellar Lines
Sites: Los Angeles, California; Englewood, Colorado; Aventura, Florida · 25 sites in all
- Investigation of Safety and Efficacy of ABP-450 for Migraine Prevention in AdultsPivotal-lookingCompleted
AEON Biopharma, Inc.Industry
NCT04845178 · 797 participants · Start Mar 1, 2021 · Primary completion Jun 19, 2024
Drug: ABP-450; Placebo · For: Migraine
Sites: Chandler, Arizona; Phoenix, Arizona; Tempe, Arizona · 62 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- off label use2,430
- drug ineffective1,941
- drug intolerance1,370
- product use in unapproved indication1,345
- headache1,188
- migraine1,122
- nausea1,111
- hypoaesthesia1,018
- maternal exposure during pregnancy981
- pain962
- hypertension934
- dizziness916
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 6 |
| 2005 | 7 |
| 2006 | 2 |
| 2007 | 3 |
| 2008 | 31 |
| 2009 | 46 |
| 2010 | 42 |
| 2011 | 94 |
| 2012 | 562 |
| 2013 | 13 |
| 2014 | 11 |
| 2015 | 12 |
| 2016 | 16 |
| 2017 | 24 |
| 2018 | 55 |
| 2019 | 138 |
| 2020 | 229 |
| 2021 | 470 |
| 2022 | 491 |
| 2023 | 560 |
| 2024 | 1,059 |
| 2025 | 1,340 |
| 2026 | 758 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Botulinum toxin type A for facial wrinkles.
Camargo CP, Xia J, Costa CS, et al. · Cochrane Database Syst Rev 2021 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Immunogenicity of DaxibotulinumtoxinA for Injection in Glabellar Lines.
Humphrey S, Dover JS, Bowsher RR, et al. · Aesthet Surg J 2023 · Randomized Controlled Trial
- Clinical Immunogenicity of DaxibotulinumtoxinA for Injection in Glabellar Lines: Pooled Data from the SAKURA Phase 3 Trials.
Gallagher CJ, Bowsher RR, Clancy A, et al. · Toxins (Basel) 2023 · Clinical Trial, Phase III, Research Support, Non-U.S. Gov't
- Efficacy and Safety of DaxibotulinumtoxinA for Injection in Cervical Dystonia: ASPEN-1 Phase 3 Randomized Controlled Trial.
Comella CL, Jankovic J, Hauser RA, et al. · Neurology 2024 · Randomized Controlled Trial, Clinical Trial, Phase III
- DaxibotulinumtoxinA for Injection for the Treatment of Glabellar Lines: Efficacy Results From SAKURA 3, a Large, Open-Label, Phase 3 Safety Study.
Fabi SG, Cohen JL, Green LJ, et al. · Dermatol Surg 2021 · Clinical Trial, Phase III, Multicenter Study
- Long-Term Safety and Efficacy of Repeat Treatments with DaxibotulinumtoxinA in Cervical Dystonia: Results from the ASPEN-Open-Label Study.
McAllister P, Patel AT, Banach M, et al. · Mov Disord Clin Pract 2025 · Clinical Trial, Phase III, Multicenter Study
Sponsor: Revance Therapeutics, Inc.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.